News
People with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.
The explosion in the use of costly GLP-1 drugs has helped fuel a 9.3% jump in per-person drug costs for CT residents.
It isn’t uncommon for insurance premiums to rise annually, but the statewide average of 28% is notably higher than the increase in years past: 5.6% in 2025, 9.7% in 2024, 10.4% in 2023 and 1.1% in ...
Novo Nordisk A/S (NYSE: NVO) has reported that it retains about sixty percent of the list price of Ozempic and Wegovy, its ...
GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...
The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...
Discover Fulton County's latest budget updates, health initiatives, and a proposed public health levy to secure vital services into the future.
New permanent tax exclusions and expanded funds usage give benefit leaders the opportunity to bolster their financial ...
The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...
5d
Money Talks News on MSNWegovy Fallout: How Novo’s Exit Hits Your Wallet and Waistline
Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...
The largest healthcare stocks by market capitalization are undergoing significant sell-offs. UnitedHealth is still a large ...
Dr Bryan Betty joined Jack Tame to discuss Wegovy – what it is, how you use it, the side effects, and why people are seeking medical treatment for their weight. A once-weekly injection for weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results